Haloperidol versus second-generation antipsychotics on the cognitive performance of individuals with schizophrenia and related disorders: pairwise meta-analysis of randomized controlled trials.

ABSTRACT:

Objective

Despite previous literature, the superiority of second-generation antipsychotics (SGAs) relative to first-generation antipsychotics - especially haloperidol - on cognitive management in schizophrenia is still controversial. Thus, we aimed to compare the effects of haloperidol versus SGAs on the cognitive performance of individuals with schizophrenia or related disorders.

Methods

We conducted an updated systematic review and nine pairwise meta-analyses of double-blinded randomized controlled trials published up to October 30th, 2022, using MEDLINE, Web of Science, and Embase.

Results

Twenty-eight trials were included, enrolling 1,932 individuals. Compared to SGAs, haloperidol performed worse on cognitive composite (mean difference [MD] -0.13; 95% confidence i

SUBMITTER: Baldez DP 

PROVIDER: S-EPMC12904266 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature